Recombinant blood products and therapeutic enzymes - Pharmaceutical Biotechnology: Concepts and Aapplications - page 370

Pineo, G. and Hull, R. 1997. Low molecular weight heparin-prophylaxis and treatment of venous thromboembo-
lism. Annual Review of Medicine 48 , 79-91.
Salzet, M. 2002. Leech thrombin inhibitors. Current Pharmaceutical Design 8 (7), 493-503.
Sohn, J.H., Kang, H.A., Rao, K.J., Kim, C.H., Choi, E.S., Chung, B.H., and Rhee, S.K. 2001. Current status of
the anticoagulant hirudin: its biotechnological production and clinical practice. Applied Microbiology and
Biotechnology 57 (5-6), 606-613.
Walker, C. and Royston, D. 2002. Thrombin generation and its inhibition: a review of the scientifi c basis and
mechanism of action of anticoagulant therapies. British Journal of anaesthesia 88 (6), 848-863.
Thrombolytics
Al-Buhairi, A. and Jan, M. 2002. Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi
Medical Journal 23 (1), 13-19.
Banerjee, A., Chisti, Y., and Banerjee, U.C. 2004. Streptokinase - a clinically useful thrombolytic agent. Biotech-
nology Advances 22 (4), 287-307.
Bansal, V. and Roychoudhury, P. 2006. Production and purifi cation of urokinase: a comprehensive review. Protein
Expression and Purifi cation 45 (1), 1-14.
Blasi, F. 1999. The urokinase receptor. A cell surface, regulated chemokine. APMIS 107 (1), 96 -101.
Castillo, P.A., Palmer, C.S., Halpern, M.T., Hatziandreu, E.J., and Gersh, B.J. 1997. Cost-effectiveness of throm-
bolytic therapy for acute myocardial infarction. Annals of Pharmacotherapy 31 (5), 596-603.
Collen, D. 1998. Staphylokinase: a potent, uniquely fi brin-selective thrombolytic agent. Nature Medicine 4 (3),
279-284.
Gillis, J.C., Wagstaff, A.J., and Goa, K.L. 1995. Alteplase. A reappraisal of its pharmacological properties and
therapeutic use in acute myocardial infarction. Drugs 50 (1), 102-136.
Marder, V. and Stewart, D. 2002. Towards safer thrombolytic therapy. Seminars in Haematology 39 (3), 206-
216.
Peng, Y., Yang, X., and Zhang, Y. 2005. Microbial fi brinolytic enzymes: an overview of source, production, prop-
erties and thrombolytic activity in vivo . Applied Microbiology and Biotechnology 69 (2), 126-132.
Perler, B. 2005. Thrombolytic therapeutics: the current state of affairs. Journal of Endovascular Therapy 12 (2),
224-232.
Preissner, K.T., Kanse, S.M., and May, A.E. 2000. Urokinase receptor: a molecular organizer in cellular com-
munication. Current Opinion in Cell Biology 12 (5), 621-628.
Rabasseda, X. 2001. Tenecteplase (TNK tissue plasminogen activator): a new fi brinolytic for the acute treatment
of myocardial infarction. Drugs of Today 37 (11), 749-760.
Verstraete, M. 2000. Third generation thrombolytic drugs. American Journal of Medicine 109 (1), 52-58.
Enzyme therapeutics
Avramis, V. and Panosyan, E. 2005. Pharmacokinetic/pharmacodynamic relationships of asparaginase
formulations - the past, the present and recommendations for the future. Clinical Pharmacokinetics 44(4),
367-393.
Barranger, J.A., Tomich, J., Weiler, S., Sakallah, S., Sansieri, C., Miffl in, T., Bahnson, A., Wei, F.S., Wei, J.F.,
Vallor, M., Nimgaonkar, M., Ball, E., Mohney, T., Dunigan., J., Ohashi, T., Bansal, V., Mannion Henderson, J.,
Liu, C.M., and Rice, E. 1995. Molecular biology of glucocerebrosidase and the treatment of Gaucher disease.
Cytokines and Molecular Therapy 1 (3), 149-163.
Chakrabarti, R. and Schuster, S. 1997. L -Asparaginase - perspectives on the mechanisms of action and resistance.
International Journal of Pediatric Haematology/Oncology 4 (6), 597-611.